Intellia Therapeutics (NASDAQ:NTLA) Stock Price Expected to Rise, Chardan Capital Analyst Says

Intellia Therapeutics (NASDAQ:NTLA) had its price objective raised by Chardan Capital from $88.00 to $91.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a buy rating on the stock. Chardan Capital also issued estimates for Intellia Therapeutics’ FY2025 earnings at ($4.14) EPS.

NTLA has been the topic of several other research reports. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. reduced their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Barclays dropped their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. The Goldman Sachs Group reduced their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $54.94.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $13.86 on Monday. The company’s 50 day moving average price is $18.26 and its 200-day moving average price is $21.85. Intellia Therapeutics has a 52-week low of $12.82 and a 52-week high of $34.87. The company has a market capitalization of $1.41 billion, a P/E ratio of -2.55 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s quarterly revenue was down 24.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.38) EPS. Analysts forecast that Intellia Therapeutics will post -5.13 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of Intellia Therapeutics during the 3rd quarter valued at approximately $417,000. Geode Capital Management LLC lifted its position in shares of Intellia Therapeutics by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock valued at $48,164,000 after buying an additional 49,367 shares during the last quarter. Barclays PLC grew its stake in shares of Intellia Therapeutics by 17.7% during the 3rd quarter. Barclays PLC now owns 292,795 shares of the company’s stock worth $6,017,000 after acquiring an additional 44,022 shares during the period. Two Sigma Advisers LP increased its holdings in Intellia Therapeutics by 33.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock worth $21,118,000 after acquiring an additional 257,700 shares during the last quarter. Finally, Sphera Funds Management LTD. raised its stake in Intellia Therapeutics by 108.8% in the 3rd quarter. Sphera Funds Management LTD. now owns 291,080 shares of the company’s stock valued at $5,982,000 after acquiring an additional 151,661 shares during the period. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.